GlassScriptPhysician profile
Randall L Snook
NPI 1558417659
$14,660.03
in general payments reported to CMS, 2019-2025
73 companies · $1,388 in 2025
The $1,388 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,049 · 2020: $2,629 · 2021: $2,826 · 2022: $1,878 · 2023: $2,110 · 2024: $1,779 · 2025: $1,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,266 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,266.02 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,757.50 | 2019-2025 | Ubrelvy, Vraylar, Synthroid |
| Astrazeneca Pharmaceuticals LP | $1,327.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,076.81 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $812.06 | 2019-2025 | |
| Allergan, INC. | $784.22 | 2019-2020 | |
| Lilly USA, LLC | $707.36 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $482.23 | 2019-2025 | Otezla, Repatha, Otezla |
| Eisai INC. | $440.84 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $408.26 | 2019-2024 | Xarelto |
| Amneal Pharmaceuticals LLC | $394.77 | 2019-2025 | Unithroid |
| Takeda Pharmaceuticals U.S.A., INC. | $332.05 | 2019-2025 | Trintellix |
| Astellas Pharma US INC | $316.52 | 2019-2025 | Veozah, Myrbetriq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $266.92 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $257.77 | 2019-2025 | Dificid, Gardasil 9, Capvaxive |
| Glaxosmithkline, LLC. | $245.68 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Snook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.